University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Beta-adrenoceptor drugs and progression to Parkinson's disease milestones in a large pooled incident cohort

Simple item page
dc.contributor.authorWijeyekoon, Ruwani S
dc.contributor.authorCamacho, Marta
dc.contributor.authorBäckström, David
dc.contributor.authorForsgren, Lars
dc.contributor.authorLawson, Rachael A
dc.contributor.authorYarnall, Alison J
dc.contributor.authorMacleod, Angus D
dc.contributor.authorCounsell, Carl E
dc.contributor.authorTysnes, Ole-Bjørn
dc.contributor.authorAlves, Guido
dc.contributor.authorMaple-Grødem, Jodi
dc.contributor.authorBarker, Roger A
dc.contributor.authorWilliams-Gray, Caroline H
dc.contributor.authorParkinson’s Incidence Cohorts Collaboration
dc.contributor.institutionUniversity of Aberdeen.Medicine, Medical Sciences & Nutritionen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Chronic Disease Research Groupen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2025-07-28T15:56:01Z
dc.date.available2025-07-28T15:56:01Z
dc.date.issued2025-07-03
dc.descriptionWe would like to thank all participants, study personnel from each study and funders of individual studies and of PICC. We would like to thank Artur Wozniak and Adrian Martin from the University of Aberdeen, Data Management Department, for their help in developing the PICC database. We acknowledge the contributions of members of the individual study groups as detailed below. CamPaIGN study: Roger A. Barker, Thomas Foltynie, Sarah L. Mason, Caroline H. Williams-Gray. ICICLE-PD Study: David Burn, Lynn Rochester, Alison J. Yarnall, Rachael A. Lawson, Gordon W. Duncan, Tien K. Khoo. NYPUM Study: Lars Forsgren, Jan Linder, Mona Edström, Jörgen Andersson, Linda Eriksson, David Bäckström, Gun-Marie Hariz, Magdalena Domellöf. ParkWest Study: ParkWest Principal investigators: Guido Alves (Norwegian Centre for Movement Disorders, Stavanger University Hospital) and Ole-Bjørn Tysnes (Haukeland University Hospital). Study personnel: Michaela Dreetz Gjerstad, Kenn Freddy Pedersen, Elin Bjelland Forsaa, Veslemøy Hamre Frantzen, Anita Laugaland, Jodi Maple- Grødem, Johannes Lange, Karen Simonsen, Eldbjørg Fiske and Ingvild Dalen (Stavanger University Hospital); Bernd Müller, Geir Olve Skeie and Marit Renså (Haukeland University Hospital); Wenche Telstad, Aliaksei Labusau and Jane Kastet (Førde Hospital); Ineke HogenEsch, Marianne Kjerandsen and Liv Kari Håland (Haugesund Hospital); Karen Herlofson, Solgunn Ongre and Siri Bruun (Sørlandet Hospital Arendal). PICNICS study: Roger A. Barker, Caroline H. Williams-Gray, Jonathan Evans, David P. Breen, Gemma Cummins, Krista Farrell, Ruwani Wijeyekoon, Kirsten Scott, Tom Stoker, Julia Greenland, Marta Camacho, Natalie Valle Guzman, Lucy Collins, Simon Stott and Sarah Mason. PINE Study: Medical: Carl E. Counsell, Kate S. M. Taylor, Robert Caslake, Angus D. Macleod, David J. M. McGhee, Diane Swallow; Research nurse/assistant: Joanne Gordon, Clare Harris, Ann Hayman, Nicola Johannesson, Hazel Forbes; Data management: Valerie Angus, Alasdair Finlayson, David Dawson, Katie Wilde, David Ritchie, Artur Wozniak; Statisticians: Neil Scott, Shona Fielding; Radiology: Prof. Alison Murray; Pathology: Ishbel Gall, Dr James MacKenzie, Prof. Colin Smith; Secretarial: Aileen Sylvester, Susan Mitchell, Pam Rebecca, Ann Christie and Diane McCosh. The CamPaIGN study has received funding from the Wellcome Trust, the Medical Research Council, the Patrick Berthoud Trust and the NIHR Cambridge Biomedical Research Centre. (NIHR203312). The ICICLE-PD study was funded by Parkinson’s UK (J-0802, G-1301, G-1507) and supported by the Lockhart Parkinson’s Disease Research Fund and the NIHR Newcastle Biomedical Research Unit and Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The NYPUM study was supported by grants from the Swedish Medical Research Council, Erling-Persson Foundation, the Swedish Brain Foundation (Hjärnfonden), Umeå University, Västerbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Swedish Parkinson Research Foundation, Kempe Foundation, Swedish PD Association, the European Research Council and the Knut and Alice Wallenberg Foundation. The Norwegian ParkWest study has received funding from the Research Council of Norway (177966), the Western Norway Regional Health Authority (911218), the Norwegian Parkinson’s Research Foundation and Rebergs Legacy. The PICNICS study was funded by the Cure Parkinson’s Trust, the Van Geest Foundation, the Medical Research Council, Parkinson’s UK and the NIHR Cambridge Biomedical Research Centre (NIHR203312). The PINE study was funded by Parkinson’s UK (grant numbers G0502, G0914 and G1302), the Scottish Chief Scientist Office (CAF/12/05, PCL/17/10), Academy of Medical Sciences, NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation and SPRING. The PICC collaboration has been supported by The Chief Scientist Office of the Scottish Government (PCL/17/10), the Academy of Medical Sciences, Parkinson’s UK (initial collaborator meeting) and the Norwegian Association for Public Health.en
dc.description.statusPeer revieweden
dc.format.extent10
dc.format.extent837676
dc.identifier305790524
dc.identifierdfe5bab5-3a1c-4b9e-b430-0d244ac9ef19
dc.identifier40610462
dc.identifier105012437673
dc.identifier.citationWijeyekoon, R S, Camacho, M, Bäckström, D, Forsgren, L, Lawson, R A, Yarnall, A J, Macleod, A D, Counsell, C E, Tysnes, O-B, Alves, G, Maple-Grødem, J, Barker, R A, Williams-Gray, C H & Parkinson’s Incidence Cohorts Collaboration 2025, 'Beta-adrenoceptor drugs and progression to Parkinson's disease milestones in a large pooled incident cohort', npj Parkinson's Disease, vol. 11, no. 1, pp. 198. https://doi.org/10.1038/s41531-025-01014-yen
dc.identifier.doi10.1038/s41531-025-01014-y
dc.identifier.iss1en
dc.identifier.issn2373-8057
dc.identifier.otherPubMedCentral: PMC12229619
dc.identifier.otherORCID: /0000-0001-6622-7839/work/188766188
dc.identifier.urihttps://hdl.handle.net/2164/25776
dc.identifier.vol11en
dc.language.isoeng
dc.relation.ispartofnpj Parkinson's Diseaseen
dc.subjectR Medicineen
dc.subjectSupplementary Dataen
dc.subjectDASen
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleBeta-adrenoceptor drugs and progression to Parkinson's disease milestones in a large pooled incident cohorten
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wijeyekoon_etal_NPIPD_Beta-adrenoceptor_Drugs_And_VoR.pdf
Size:
818.04 KB
Format:
Adobe Portable Document Format
Download

Collections

All research